Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson s Disease Dementia (PDD)

What we are studying

The purpose of this research study is to find out what effects (good and bad) LY3154207 has on a person and his/her condition (Parkinson's disease with dementia). The main reason for anyone to take part in this study is not to treat a condition but to help in answering the following research question: How does LY3154207 compare with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson’s disease dementia? LY3154207 is an investigational drug that is not approved by the FDA.

Who is Eligible

• Genders:
  • Men
  • Women
• Races:
  • White
  • African American
  • Asian
  • American Indian or Alaska Native
  • Native Hawaiian or Pacific Islander
  • Other
• All Ethnicities
• Ages 40 - 85

Eligibility Criteria

• *Must be diagnosed with Parkinson's disease with symptoms for at least 2 years *Diagnosed with dementia *No uncontrolled hypertension *Medications stable at least 4 weeks *Cannot have Deep Brain Stimulation (DBS)

What is involved

• The study lasts 18 weeks. As part of the study you will undergo vitals
• Blood draws
• Ecgs (to check your heart)
• Questionnaires
• And memory tests.

Compensation

You will received compensation for each visit completed.

Contact Information

Study Coordinator

Jessica Dimos

Email

[email protected]

Phone

-8694

Principal Investigator

Mustafa Siddiqui, MD